Stock Events

Stock Events

Vaxart 

€0.38
253
+€0.11+41.79% Tuesday 06:40

Statistics

Day High
0.38
Day Low
0.38
52W High
-
52W Low
-
Volume
2,600
Avg. Volume
-
Mkt Cap
91.23M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Nov 12
€9.44
Oct 12
€9.42
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

6MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.11
-0.07
-0.02
0.02
Expected EPS
0.02
Actual EPS
N/A

Financials

-231.46%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
54.82MRevenue
-126.89MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NB11.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novavax
NVAX
Mkt Cap1.34B
Novavax is a direct competitor in the development of vaccines, including those for COVID-19, similar to Vaxart's oral vaccine efforts.
Moderna
MRNA
Mkt Cap20.12B
Moderna is a leader in mRNA vaccine technology, competing in the same space as Vaxart's novel vaccine platform.
Pfizer
PFE
Mkt Cap153.59B
Pfizer, with its COVID-19 vaccine developed in collaboration with BioNTech, competes in the vaccine market, including areas Vaxart is targeting.
BioNTech
BNTX
Mkt Cap26.67B
BioNTech partners with Pfizer on COVID-19 vaccines, directly competing with Vaxart's vaccine development efforts.
Johnson & Johnson
JNJ
Mkt Cap547.64B
Johnson & Johnson developed a COVID-19 vaccine, competing in the broader vaccine market where Vaxart is also a player.
Astrazeneca
AZN
Mkt Cap294.17B
AstraZeneca competes in the COVID-19 vaccine space, an area where Vaxart is also trying to make an impact with its oral vaccine candidates.
Inovio Pharmaceuticals
INO
Mkt Cap93.83M
Inovio Pharmaceuticals is focused on DNA medicines, including vaccines, making it a competitor in the innovative vaccine technology space like Vaxart.
Sanofi
SNY
Mkt Cap112.08B
Sanofi is a large pharmaceutical company with a broad vaccine portfolio, competing in the same market as Vaxart.
GSK
GSK
Mkt Cap108.66B
GlaxoSmithKline has a significant presence in the vaccine market, making it a competitor to Vaxart in the quest to develop and commercialize vaccines.

About

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Show more...
CEO
Mr. Steven Lo
Employees
105
Country
United States
ISIN
US92243A2006
WKN
000A2JD8X

Listings

MX
MX
VXRT.MX
MU
DE
NB11.MU
OTC Link
US
VXRT

0 Comments

Share your thoughts

FAQ

What is Vaxart stock price today?▼
The current price of NB11.F is €0.38 EUR — it has increased by +41.79% in the past 24 hours. Watch Vaxart stock price performance more closely on the chart.
What is Vaxart stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Vaxart stocks are traded under the ticker NB11.F.
Is Vaxart stock price growing?▼
NB11.F stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Vaxart has showed a -3.7% decrease.
What is Vaxart market cap?▼
Today Vaxart has the market capitalization of 91.23M
When is the next Vaxart earnings date?▼
Vaxart is going to release the next earnings report on May 06, 2026.
What were Vaxart earnings last quarter?▼
NB11.F earnings for the last quarter are -0.1 EUR per share, whereas the estimation was -0.04 EUR resulting in a -120% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Vaxart revenue for the last year?▼
Vaxart revenue for the last year amounts to 54.82M EUR.
What is Vaxart net income for the last year?▼
NB11.F net income for the last year is -126.89M EUR.
Does Vaxart pay dividends?▼
Yes, NB11.F dividends are paid en. The last dividend per share was 9.44 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Vaxart have?▼
As of April 29, 2026, the company has 105 employees.
In which sector is Vaxart located?▼
Vaxart operates in the Health & Wellness sector.
When did Vaxart complete a stock split?▼
The last stock split for Vaxart was on February 15, 2018 with a ratio of 1:11.
Where is Vaxart headquartered?▼
Vaxart is headquartered in South San Francisco, United States.